As psychedelic treatments advance through clinical research, investigators are increasingly examining not only what drug is administered, but what actually happens in the room while patients experience its effects. New interventional psychiatry research suggests that psilocybin support for PTSD may look considerably different from conventional psychotherapy, with silence occupying most of the administration session.
Published in the Journal of Psychopharmacology, the study analyzed interactions between participants and support providers during a clinical trial of 25 mg COMP360 psilocybin in 22 adults with post-traumatic stress disorder. Rather than finding continuous therapeutic dialogue, researchers documented an environment characterized primarily by quiet observation, participant introspection, and limited verbal intervention.
Rethinking The Role Of Support During Psychedelic Treatment
Psychological support has become a central component of many psychedelic clinical trials. Yet what “support” actually means can vary substantially across treatment models.
In conventional psychotherapy, conversation is typically the primary mechanism through which treatment occurs. Clinicians may ask questions, challenge interpretations, introduce coping strategies, or guide patients through memories and emotional responses.
Psychedelic administration creates a different clinical environment. Participants may experience profound changes in perception, emotion, memory, and self-awareness for several hours. This raises an important question for the field: Should support providers actively guide that experience, or should they primarily create a safe environment in which it can unfold?
The new analysis provides unusually detailed evidence about how one clinical model approaches that question.
Measuring What Actually Happened In The Room
Researchers examined audio transcripts collected during a 12-week trial evaluating COMP360 psilocybin for PTSD. Instead of relying only on treatment manuals or descriptions of therapeutic philosophy, the team measured actual speech production.
Words per minute were calculated for both participants and support providers during preparation, psilocybin administration, and follow-up sessions.
The contrast was substantial. During administration sessions, an average of 78% of the time contained no speech from either the participant or support provider. During preparation and follow-up sessions, silence accounted for approximately 25% to 30% of the time.
This distinction suggests that the administration session was not simply another psychotherapy appointment conducted while a participant was under the effects of psilocybin.
Psilocybin Support For PTSD May Depend On Saying Less
The researchers also analyzed interviews conducted after dosing to understand how participants experienced the support model.
Three themes emerged. First, support was minimally enacted but remained meaningful to participants. In other words, support providers did not need to speak continuously for their presence to be experienced as important.
Second, the non-directive approach appeared to encourage autonomy. Participants were given space to engage with their internal experience rather than having its direction determined through ongoing conversation.
Third, when verbal support was provided during altered states of consciousness, reassurance and validation were among its primary forms.
Together, these observations suggest that therapeutic presence and therapeutic conversation may represent distinct components of psychedelic treatment.
Why Silence Could Matter During The Psychedelic State
Psilocybin can produce an intensely introspective state involving changes in emotional processing, autobiographical memory, perception, and sense of self. Frequent external conversation could potentially redirect attention away from that internal experience.
A quieter environment may allow participants to remain engaged with thoughts, emotions, memories, or sensations as they arise.
Importantly, this does not mean participants were simply left alone. The model involved preparation, monitoring, and support from trained providers. The distinction is that support during drug administration was largely non-directive rather than conversation-driven.
That difference could become increasingly important as researchers work to define which components of psychedelic treatment contribute to safety, therapeutic outcomes, and scalability.
A Different Model From Conventional Psychotherapy
The findings also help clarify terminology surrounding psychedelic treatment.
Phrases such as “psilocybin-assisted psychotherapy” can imply that psychotherapy and drug administration occur simultaneously throughout the dosing session. The observed sessions suggest a more nuanced structure.
Preparation and follow-up involved substantially more verbal interaction, while the psychedelic administration period was dominated by silence and introspection.
The authors note that this approach differs from many conventional psychotherapies, MDMA-assisted therapy protocols, and psycholytic approaches in which verbal therapeutic interaction may play a larger role during drug effects.
What This Could Mean For Psychedelic Care
Understanding the amount and type of support required during psychedelic administration has implications beyond terminology. It could influence provider training, treatment protocols, staffing models, clinical infrastructure, and future regulatory frameworks.
The findings should not be interpreted as evidence that silence itself produces better PTSD outcomes. The study involved only 22 participants, and its primary purpose was to characterize how monitoring and support were delivered and experienced rather than determine whether one support style is superior.
Still, documenting what actually happens inside psychedelic treatment sessions addresses an important gap. As psychedelic medicine develops, researchers will need to distinguish the pharmacological effects of compounds from the influence of preparation, environment, provider presence, verbal interaction, and post-treatment integration.
For psilocybin support for PTSD, this study suggests that effective clinical presence may not always require active conversation. Sometimes the provider’s role may be to create the conditions for an experience to unfold safely, while knowing when reassurance or intervention is needed.
The next phase of research will need to determine how these different elements interact and whether particular support models are better suited to specific patients, conditions, or psychedelic compounds.
Citations
- Dougherty RF, Modlin NL, McGowan NM, et al. “Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.” Journal of Psychopharmacology. Published online July 16, 2026. DOI: 10.1177/02698811261464988. https://journals.sagepub.com/doi/10.1177/02698811261464988
- ClinicalTrials.gov. “The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder.” NCT05312151. Phase 2, open-label study of 25 mg COMP360 psilocybin in 22 participants. https://clinicaltrials.gov/study/NCT05312151?utm_source=chatgpt.com
Explore more at https://www.interventionalpsychiatry.org/
